



IACUC THREE I's	
IBC	
IRB BIOSECURITY RA	
RI COMPLIANCE REGULATORY	

THREE I's: and RESEARCH INTEGRITY™: COMPLIANCE, ETHICS and BIOSECURITY ... Building Resilience

Day 1 **MONDAY** **APRIL 27, 2026** **DRAFT CONFERENCE AGENDA**

	VIRTUAL WHOVA NETWORKING
10:00 AM	WELCOME & INTRODUCTIONS MeRTEC
10:10 AM- 10:50 AM	KEYNOTE ADDRESS THREE I's SESSION
Keynote THREE I's	TBA BARBARA EMILY BIERER, MD PROFESSOR OF MEDICINE (PEDIATRICS), HMS MEMBER, HMS CENTER FOR BIOETHICS Barbara E. Bierer, M.D., is a hematologist-oncologist and professor of medicine at Harvard Medical School (HMS) and the Brigham and Women's Hospital (BWH). Dr. Bierer is the faculty director of the Multi-Regional Clinical Trials Center of BWH and Harvard (MRCT Center), a collaborative effort to improve the ethics, conduct, and regulatory environment of multi-site and international clinical trials. She is also the director of the Regulatory Foundations, Ethics, and Law program at the Harvard Catalyst and director of regulatory policy for SMART IRB. Dr. Bierer serves as faculty at the Center for Bioethics, HMS, and affiliate faculty at the Petrie-Flom Center for Health Law at Harvard Law School. She is a co-founder of the COVID-19 Collaboration Platform and of the non-profit Vivli, a global clinical research data-sharing platform. From 2003 to 2014, Dr. Bierer served as senior vice president of research at BWH where she founded the Brigham Research Institute and the Brigham Innovation Hub. She was previously chair of SACHRP and has served or currently serves on the board of directors of AAHRPP, PRIMR, MSH, Vivli, North Star IRB, and the Edward P. Evans Foundation. She has authored over 275 publications.
11:00 AM – 11:40 AM	REGULATORY BREAKOUT SESSIONS

	<p style="text-align: center;">IACUC</p> <p style="text-align: center;">OLAW UPDATE</p> <p>NEERA V. GOPEE, DVM, PhD, DABT, DACLAM ASSOCIATE DIRECTOR FOR ANIMAL WELFARE POLICY OFFICE OF LABORATORY ANIMAL WELFARE, NIH</p>	<p style="text-align: center;">IBC</p> <p>KATHRYN HARRIS, PhD SENIOR OUTREACH AND EDUCATION ANALYST OFFICE OF SCIENCE POLICY NIH</p>	<p style="text-align: center;">IRB</p> <p style="text-align: center;">TBA</p>
11:40 AM – 11:50 AM	BREAK		
11:50 AM - 12:30 PM	BREAKOUT SESSIONS		
	<p style="text-align: center;">THREE I's</p> <p style="text-align: center;">HOW DO WE TALK ABOUT WHAT WE DO? <i>What is our Value?</i></p> <p style="text-align: center;">MODERATOR: CECE BROTCHE-FINE, DBE, EXECUTIVE DIRECTOR, ETHICS, NOVARTIS</p> <p style="text-align: center;">SALLY THOMPSON-IRITANI, DVM, PHD AVP, ANIMAL CARE, OUTREACH, & 3RS UNIVERSITY of WASHINGTON</p> <p style="text-align: center;">CHRIS MANGELLI, JD DIRECTOR OFFICE OF RESEARCH INTEGRITY (ORI) BALL STATE UNIVERSITY</p> <p style="text-align: center;">RACHEL FRISBIE, PhD COMPUTATIONAL SCIENCE EDUCATION RESEARCH MICHIGAN STATE UNIVERSITY</p>	<p style="text-align: center;">IBC IRB</p> <p style="text-align: center;">BRIDGING THE GAP: EFFECTIVE COLLABORATION BETWEEN IBC & IRB FOR CLINICAL RESEARCH</p> <p style="text-align: center;">RYAN SCHLIMGEN, PhD MASS GENERAL BRIGHAM</p>	<p style="text-align: center;">RI COMPLIANCE</p> <p style="text-align: center;">THE GOOD BAD AND THE UGLY OF AI IN RESEARCH</p> <p style="text-align: center;">KELÉ PIPER CHIEF RESEARCH COMPLIANCE OFFICER COMPLIANCE, AUDIT & BUSINESS INTEGRITY MASS GENERAL BRIGHAM</p> <p>The emergence of generative AI tools presents exciting opportunities for advancing research and innovation; however, concerns exist regarding the inherent limitations of the tools and the risks associated with their use.</p> <p>Objectives:</p> <ol style="list-style-type: none"> 1. The bad: Strategies to deal with the bad before achieving the ugly in a research integrity program; finding the right balance for researchers 2. The good: Considerations for AI tools used to enhance and improve submissions of research work; effective communication to prevent misconceptions 3. The flat out ugly: What to do when the worst happens without going overboard with overbearing, labor-intensive fixes

12:30 PM - 1:00 PM	LUNCH & Networking!
1:00 PM – 2:00 PM	RESEARCH COMPLIANCE, CONFLICT MANAGEMENT AND COMPASSION (3CS) LLIAM HARRISON, MA JD CIP CMED, HURON NIEM-TZU “REBECCA” CHEN, MS, MED, CCRP RUTGERS UNIVERSITY HUMAN SUBJECTS PROTECTION SENIOR ANALYST & RUTGERS CLINICALTRIALS.GOV ADMINISTRATOR
COMPLIANCE	Research administrators and compliance professionals share a common purpose with researchers: advancing knowledge and sound science. Yet human factors—stress, burnout, and fraught interactions—often turn shared purpose into friction. This session will give attendees a taste of how approaching compliance from a perspective of compassion-informed conflict management can smooth that friction, cultivate and strengthen relationships with a shared aim of doing good, ethical research. Participants will leave with a sampling of strategies and practices to implement the 3Cs approach to reduce risk, strengthen trust, and improve adherence without sacrificing pace or quality.
1:00 PM - 2:00 PM	WHY RESEARCH OVERSIGHT AND COMPLIANCE PROGRAMS SHOULD CARE ABOUT PEER REVIEW BENJAMIN C. SILVERMAN, MD, SENIOR IRB CHAIR, MASS GENERAL BRIGHAM COURTNEY KARMELOTA, CHIEF OF STAFF, THE OFFICE FOR RESEARCH PROTECTIONS; EXECUTIVE DIRECTOR, ETHICAL RESEARCH AND OUTREACH; AND RESEARCH INTEGRITY OFFICER AT PENN STATE
THREE I’s	Peer review is a quality control mechanism in academia, where experts evaluate a research paper, scholarly work, or grant proposal before it is published or funded. It aims to ensure the scientific validity, originality, quality, and integrity of the work. While peer review remains a key component of the research process, over reliance on peer review as a mechanism for ensuring ethical, compliant, and quality research ignores its problems. Having been peer reviewers and researchers who have gone through the peer review process, the presenters will discuss the relevance of peer review for research oversight and compliance professionals, along with how the inherent flaws of the current peer review system can inadvertently enable research misconduct and noncompliance. This session will delve into how the broken peer review system directly impacts staff in research administration, including human and animal research oversight programs. In particular, the presenters will discuss how jobs that promote or monitor for research integrity and compliance have more importance than ever knowing that we cannot solely rely on peer review as a marker of research quality, integrity, and compliance. Further, not only are HRPPs/IRBs/IACUCs and research compliance offices impacted by a broken peer review system, e.g. due to potential noncompliance or research integrity issues, but they also face some of the same challenges and can learn from these shared experiences. At the end of this session, participants will be able to: 1) Understand what peer review is and what peer review is not and appreciate its relevance to research oversight and compliance work. 2) Identify Limitations of Peer Review: Discuss the inherent flaws and limitations of the peer review process, particularly its potential to enable research misconduct and noncompliance. 3) Examine the Impact of Peer Review Failures on Research Administration: Analyze how shortcomings in the peer review system affect research administrators and research oversight program staff and their roles in maintaining research integrity and compliance. 4) Propose Solutions to Strengthen Research Integrity and Compliance: Suggest practical approaches for improving the research oversight process, emphasizing the need for more robust systems beyond peer review to ensure ethical, compliant, and high-quality research.
2:00PM	SEE YOU IN THE AM!